Stay updated on Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.

Latest updates to the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page
- Check6 days agoChange DetectedEnrollment status updated to 'No longer looking for participants', and new help sections were added (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention / Treatment heading was reformatted to 'Intervention/Treatment', and the revision tag updated from v3.5.5 to v3.6.0.SummaryDifference0.2%

- Check13 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating an administrative update to the study record rather than a substantive change to study details.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page’s revision tag was updated from v3.5.3 to v3.5.4, indicating a small update to the study record metadata on ClinicalTrials.gov.SummaryDifference0.0%

- Check49 days agoChange DetectedTaoyuan District, Taiwan, 333 was replaced with Taoyuan, Taiwan, 333 in the Locations section to standardize the city designation for the study site.SummaryDifference0.0%

- Check57 days agoChange DetectedUpdated the page’s footer revision/version indicator from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check64 days agoChange DetectedLocation entries were updated to list Viña del Mar as Viña del Mar, Valparaiso, Chile (postal code 2520598) and Valparaiso as a separate location, and Ono Pharmaceutical Co., Ltd. was added as a collaborator; the revision version updated from v3.5.0 to v3.5.2.SummaryDifference0.3%

Stay in the know with updates to Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.